Jesse Swen
Hoogleraar Klinische Farmacie, in het bijzonder translationele farmacogenetica
- Naam
- Prof.dr. J.J. Swen
- Telefoon
- +31 71 526 2790
- j.j.swen@lumc.nl
- ORCID iD
- 0000-0002-3965-5552
Jesse J. Swen is hoogleraar klinische farmacie, in het bijzonder translationele farmacogenetica. Hij is ziekenhuisapotheker- klinisch farmacoloog en sectiehoofd van het klinisch farmaceutisch laboratorium van de afdeling klinische farmacie en toxicologie van het Leids Universitair Medisch Centrum (LUMC).
Meer informatie over Jesse Swen
Jesse J. Swen is hoogleraar klinische farmacie, in het bijzonder translationele farmacogenetica. Hij is ziekenhuisapotheker- klinisch farmacoloog en sectiehoofd van het klinisch farmaceutisch laboratorium van de afdeling klinische farmacie en toxicologie van het Leids Universitair Medisch Centrum (LUMC).
Klinische Farmacie
Klinische Farmacie richt zich op het verzorgen en waarborgen van een optimale behandeling met geneesmiddelen (NWA Route Personalised medicine). De reactie op geneesmiddelen verschilt sterk tussen patiënten en een deel van deze verschillen wordt veroorzaakt door genetische variatie. Farmacogenetica onderzoekt in welke mate verschillen in het genetisch profiel een verklaring vormt en kan worden gebruikt om bijwerkingen en ineffectiviteit van geneesmiddelen te voorkomen. Door onze sterk toegenomen kennis op het gebied van de genetica wordt het mogelijk om op basis van een genetisch profiel voor start van de behandeling de keuze van het middel en dosering te individualiseren.
Wetenschappelijke carrière
Jesse Swen behaalde zijn apothekersdiploma aan de Universiteit Utrecht in 2004. Zijn specialisatie tot ziekenhuisapotheker combineerde hij met promotieonderzoek. De titel van zijn proefschrift (2011) luidt “Translating Pharmacogenetics to Primary Care”. Na zijn opleiding en promotie startte hij als onderzoeker bij de PharmGKB groep aan de Stanford universiteit waarna hij werd gevraagd terug te komen naar het LUMC als ziekenhuisapotheker-onderzoeker. In 2022 werd hij benoemd tot hoogleraar Klinische Farmacie, in het bijzonder translationele farmacogenetica bij het LUMC wat hij combineert met zijn werk als sectiehoofd van het Klinisch Farmaceutisch Laboratorium.
Hoogleraar Klinische Farmacie, in het bijzonder translationele farmacogenetica
- Faculteit Geneeskunde
- Divisie 4
- Klinische Farmacie en Toxicologie
- Marok, F.Z.; Wojtyniak, J.G.; Selzer, D.; Dallmann, R.; Swen, J.J.; Guchelaar, H.J.; Schwab, M. & Lehr, T. (2024), Personalized chronomodulated 5-Fluorouracil treatment, Clinical Pharmacology & Therapeutics.
- Zhai, Q.L.; Moes, D.J.A.R.; Gelder, T. van; Lee, M. van der; Sanders, J.S.; Bemelman, F.J.; Fijter, J.W. de; Klein, K.; Schwab, M. & Swen, J.J. (2024), The effect of genetic variants in the transcription factor TSPYL family on the CYP3A4 mediated cyclosporine metabolism in kidney transplant patients, Clinical and Translational Science 17(2).
- Jong, L.M. de; Boussallami, S.; Sanchez-Lopez, E.; Giera, M.; Tushuizen, M.E.; Hoekstra, M.; Hawinkels, L.J.A.C.; Rissmann, R.; Swen, J.J. & Manson, M.L. (2023), The impact of CYP2C19 genotype on phenoconversion by concomitant medication, Frontiers in Pharmacology 14.
- Knikman, J.E.; Wilting, T.A.; Lopez-Yurda, M.; Henricks, L.M.; Lunenburg, C.A.T.C.; Man, F.M. de; Meulendijks, D.; Nieboer, P.; Droogendijk, H.J.; Creemers, G.J.; Mandigers, C.M.P.W.; Imholz, A.L.T.; Mathijssen, R.H.J.; Portielje, J.E.A.; Valkenburg-van Iersel, L.; Vulink, A.; Poel, M.H.W. van der; Baars, A.; Swen, J.J.; Gelderblom, H.; Schellens, J.H.M.; Beijnen, J.H.; Guchelaar, H.J. & Cats, A. (2023), Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy, Journal of Clinical Oncology 41(35): 5411-+.
- Lyousoufi, M.; Lafeber, I.; Kweekel, D.; Winter, B.C.M. de; Swen, J.J.; Brun, P.P.H. le; Bijleveld-Olierook, E.C.M.; Gelder, T. van; Guchelaar, H.J.; Moes, D.J.A.R. & Schimmel, K.J.M. (2023), Development and bioequivalence of 3D-Printed medication at the point-of-care, Clinical Pharmacology & Therapeutics 113(5).
- Loer, H.L.H.; Feick, D.; Rudesheim, S.; Selzer, D.; Schwab, M.; Teutonico, D.; Frechen, S.; Lee, M. van der; Moes, D.J.A.R.; Swen, J.J. & Lehr, T. (2023), Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions, CPT: Pharmacometrics and Systems Pharmacology 12(5).
- Peruzzi, E.; Roncato, R.; Mattia, E. de; Bignucolo, A.; Swen, J.J.; Guchelaar, H.J.; Toffoli, G. & Cecchin, E. (2023), Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice, British Journal of Clinical Pharmacology.
- Beunk, L.; Nijenhuis, M.; Soree, B.; Boer-Veger, N.J. de; Buunk, A.M.; Guchelaar, H.J.; Houwink, E.J.F.; Risselada, A.; Rongen, G.A.P.J.M.; Schaik, R.H.N. van; Swen, J.J.; Touw, D.; Westrhenen, R. van; Deneer, V.H.M. & Weide, J. van der (2023), Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics, European Journal of Human Genetics.
- Levens, A.D.; Haan, M.C. den; Jukema, J.W.; Heringa, M.; Hout, W.B. van den; Moes, D.J.A.R. & Swen, J.J. (2023), Feasibility of Community Pharmacist-Initiated and point-of-care CYP2C19 genotype-guided de-escalation of oral P2Y12 inhibitors, Genes 14(3).
- Gruil, N. de; Böhringer, S.; Groot, S. de; Pijl, H.; Kroep, J.R. & Swen, J.J. (2023), IGF1 and insulin receptor single nucleotide variants associated with response in HER2-negative breast cancer patients treated with neoadjuvant chemotherapy with or without a fasting mimicking diet (BOOG 2013-04 DIRECT trial), Cancers 15(24).
- Chui, C.Y.; Moes, D.J.A.R.; Koolen, S.L.W.; Swen, J.J. & Gelderblom, H. (2023), Pharmacokinetic profile of irinotecan in patients with chronic kidney disease, British Journal of Clinical Pharmacology 89(9).
- Eektimmerman, F.; Swen, J.J.; Broeder, A.A. den; Hazes, J.M.W.; Kurreeman, F.S.; Verstappen, S.M.M.; Nair, N.; Pawlik, A.; Nurmohamed, M.T.; Dolzan, V.; Bohringer, S.; Allaart, C.F. & Guchelaar, H.J. (2023), Genome-wide association study of methotrexate-induced liver injury in rheumatoid arthritis patients, Clinical Pharmacology & Therapeutics 113(4).
- Souwer, E.T.D.; Sanchez-Spitman, A.; Moes, D.J.A.R.; Gelderblom, H.; Swen, J.J.; Portielje, J.E.A.; Guchelaar, H.J. & Gelder, T. van (2023), Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer, Breast Cancer Research and Treatment 199.
- Jansen, M.E.; Rigter, T.; Fleur, T.M.C.; Souverein, P.C.; Verschuren, W.M.M.; Vijverberg, S.J.; Swen, J.J.; Rodenburg, W. & Cornel, M.C. (2023), Predictive value of SLCO1B1 c.521T>C polymorphism on observed changes in the treatment of 1136 statin-users, Genes 14(2).
- Guchelaar, H.J. & Swen, J. (2023), Reply to: Temporary Like Achilles: Pre-emptive germline pharmacogenetic testing, Basic and Clinical Pharmacology and Toxicology 133(4): 400-401.
- Veringa, A.; Bruggemann, R.J.; Span, L.F.R.; Biemond, B.J.; Boer, M.G.J. de; Heuvel, E.R. van den; Klein, S.K.; Kraemer, D.; Minnema, M.C.; Prakken, N.H.J.; Rijnders, B.J.A.; Swen, J.J.; Verweij, P.E.; Wondergem, M.J.; Ypma, P.F.; Blijlevens, N.; Kosterink, J.G.W.; Werf, T.S. van der; Alffenaar, J.W.C. & Voriconazole ZonMw Study Grp (2023), Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients, International Journal of Antimicrobial Agents 61(2).
- Peeters, S.L.; Deenen, M.J.; Thijs, A.M.; Hulshof, E.C.; Mathijssen, R.H.; Gelderblom, H.; Guchelaar, H.J. & Swen, J.J. (2023), UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety, Pharmacogenomics 24(9): 435-439.
- Koufaki, M.I.; Fragoulakis, V.; Diaz-Villamarin, X.; Karamperis, K.; Vozikis, A.; Swen, J.J.; Davila-Fajardo, C.L.; Vasileiou, K.Z.; Patrinos, G.P. & Mitropoulou, C. (2023), Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study, Human Genomics 17(1).
- Feick, D.; Rudesheim, S.; Marok, F.Z.; Selzer, D.; Loer, H.L.H.; Teutonico, D.; Frechen, S.; Lee, M. van der; Moes, D.J.A.R.; Swen, J.J.; Schwab, M. & Lehr, T. (2023), Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug-drug-gene interaction network, CPT: Pharmacometrics and Systems Pharmacology 12(8).
- Hulshof, E.C.; With, M. de; Man, F.M. de; Creemers, G.J.; Deiman, B.A.L.M.; Swen, J.J.; Houterman, S.; Koolen, S.L.W.; Bins, S.; Thijs, A.M.J.; Laven, M.M.J.; Hovels, A.M.; Luelmo, S.A.C.; Houtsma, D.; Shulman, K.; McLeod, H.L.; Schaik, R.H.N. van; Guchelaar, H.J.; Mathijssen, R.H.J.; Gelderblom, H. & Deenen, M.J. (2022), UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients, European Journal of Cancer 162: 148-157.
- Diekstra, M.H.M.; Swen, J.J.; Zanden, L.F.M. van der; Vermeulen, S.H.; , E. boven; Mathijssen, R.H.J.; Fukunaga, K.; Mushiroda, T.; Hongo, F.; Oosterwijk, E.; Cambon-Thomsen, A.; Castellano, D.; Fritsch, A.; Donas, J.G.; Rodriguez-Antona, C.; Ruijtenbeek, R.; Radu, M.T.; Eisen, T.; Junker, K.; Roessler, M.; Jaehde, U.; Miki, T.; Bohringer, S.; Kubo, M.; Kiemeney, L.A.L.M. & Guchelaar, H.J. (2022), Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 that correlate with efficacy outcomes in metastatic renal cell carcinoma patients treated with sunitinib, Cancers 14(12).
- Zwart, T.C.; Metscher, E.; Boog, P.J.M. van der; Swen, J.J.; Fijter, J.W. de; Guchelaar, H.J.; Vries, A.P.J. de & Moes, D.J.A.R. (2022), Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients, British Journal of Clinical Pharmacology.
- Blagec, K.; Swen, J.J.; Koopmann, R.; Cheung, K.C.; Crommentuijn-van Rhenen, M.; Holsappel, I.; Konta, L.; Ott, S.; Steinberger, D.; Xu, H.; Cecchin, E.; Dolzan, V.; Davila-Fajardo, C.L.; Patrinos, G.P.; Sunder-Plassmann, G.; Turner, R.M.; Pirmohamed, M.; Guchelaar, H.J.; Samwald, M. & Ubiquitous Pharmacogenomics Consortium (2022), Pharmacogenomics decision support in the U-PGx project, PLoS ONE 17(6).
- Zhai, Q.L.; Lee, M. van der; Gelder, T. van & Swen, J.J. (2022), Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity, Frontiers in Pharmacology 13.
- Wouden, C.H. van der; Guchelaar, H.J. & Swen, J.J. (2022), Precision Medicine Using Pharmacogenomic Panel-Testing Current Status and Future Perspectives, Clinics in Laboratory Medicine 42(4): 587-602.
- Barker, C.I.S.; Groeneweg, G.; Maitland-van der Zee, A.H.; Rieder, M.J.; Hawcutt, D.B.; Hubbard, T.J.; Swen, J.J. & Carleton, B.C. (2022), Pharmacogenomic testing in paediatrics, British Journal of Clinical Pharmacology.
- With, M. de; Knikman, J.; Schellens, J.H.M.; Gelderblom, H.; Cats, A.; Guchelaar, H.J.; Mathijssen, R.H.J.; Swen, J.J. & Meulendijks, D. (2022), Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters", Clinical Pharmacology & Therapeutics.
- Bernsen, E.C.; Hanff, L.M.; Haveman, L.M.; Tops, B.B.J.; Lee, M. van der; Swen, J.J.; Huitema, A.D.R. & Diekstra, M.H.M. (2022), Genetic variants found in paediatric oncology patients with severe chemotherapy-induced toxicity, Journal of Oncology Pharmacy Practice.
- Hulshof, E.C.; Deenen, M.J.; Nijenhuis, M.; Soree, B.; Boer-Veger, N.J. de; Buunk, A.M.; Houwink, E.J.F.; Risselada, A.; Rongen, G.A.P.J.M.; Schaik, R.H.N. van; Touw, D.J.; Weide, J. van der; Westrhenen, R. van; Deneer, V.H.M.; Guchelaar, H.J. & Swen, J.J. (2022), Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan, European Journal of Human Genetics.
- Nijenhuis, M.; Soree, B.; Jama, W.O.M.; Boer-Veger, N.J. de; Buunk, A.M.; Guchelaar, H.J.; Houwink, E.J.F.; Rongen, G.A.; Schaik, R.H.N. van; Swen, J.J.; Touw, D.; Weide, J. van der; Westrhenen, R. van; Deneer, V.H.M. & Risselada, A. (2022), Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate, European Journal of Human Genetics.
- Klomp, S.D.; Meziyerh, S.; Vissers, M.F.J.M.; Moes, D.J.A.R.; Arends, E.J.; Teng, Y.K.O.; Swen, J.J. & Vries, A.P.J. de (2022), Increased tacrolimus exposure in kidney transplant recipients with COVID-19 , Transplant International 35.
- Lee, M. van der & Swen, J.J. (2022), Artificial intelligence in pharmacology research and practice, Clinical and Translational Science 16(1).
- Moes, D.J.A.R.; Westerloo, D.J. van; Arend, S.M.; Swen, J.J.; Vries, A. de; Guchelaar, H.J.; Joosten, S.A.; Boer, M.G.J. de; Gelder, T. van & Paassen, J. van (2022), Towards fixed dosing of tocilizumab in ICU-admitted COVID-19 patients, Clinical Pharmacokinetics 61.
- Wouden, C.H. van der; Marck, H.; Guchelaar, H.J.; Swen, J.J. & Hout, W.B. van den (2022), Cost-effectiveness of pharmacogenomics-guided prescribing to prevent gene-drug-related deaths, Frontiers in Pharmacology 13.
- With, M. de; Knikman, J.; Man, F.M. de; Lunenburg, C.A.T.C.; Henricks, L.M.; Kuilenburg, A.B.P. van; Maring, J.G.; Staveren, M.C. van; Vries, N. de; Rosing, H.; Beijnen, J.H.; Pluim, D.; Modak, A.; Imholz, A.L.T.; Schaik, R.H.N. van; Schellens, J.H.M.; Gelderblom, H.; Cats, A.; Guchelaar, H.J.; Mathijssen, R.H.J.; Swen, J.J. & Meulendijks, D. (2022), Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil, Clinical Pharmacology & Therapeutics 112(1): 62-68.
- Heteren, D.M. van; Lijfering, W.M.; Meer, F.J.M. van der; Reitsma, P.H.; Swen, J.J.; Bos, M.H.A. & Rein, N. van (2022), Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists, Journal of Internal Medicine 293(1).
- Pol, K.H. van der; Nijenhuis, M.; Soree, B.; Boer-Veger, N.J. de; Buunk, A.M.; Guchelaar, H.J.; Risselada, A.; Schaik, R.H.N. van; Swen, J.J.; Touw, D.; Weide, J. van der; Westrhenen, R. van; Deneer, V.H.M.; Houwink, E.J.F. & Rongen, G.A. (2022), Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and allopurinol, and MTHFR, folic acid and methotrexate, European Journal of Human Genetics.
- Jong, L.M. de; Klomp, S.D.; Treijtel, N.; Rissmann, R.; Swen, J.J. & Manson, M.L. (2022), A systematic review on disease-drug-drug interactions with immunomodulating drugs, British Journal of Clinical Pharmacology 88(10).
- Tafazoli, A.; Lee, M. van der; Swen, J.J.; Zeller, A.; Wawrusiewicz-Kurylonek, N.; Mei, H.L.; Vorderman, R.H.P.; Konopko, K.; Zankiewicz, A. & Miltyk, W. (2022), Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling, Pharmacogenomics Journal 22.
- Blom, M.; Pico-Knijnenburg, I.; Montfrans, J.M. van; Bredius, R.G.M.; Burg, M. van der; Swen, J.J. & Berghuis, D. (2021), Abnormal Results of Newborn Screening for SCID After Azathioprine Exposure In Utero: Benefit of TPMT Genotyping in Both Mother and Child, Journal of Clinical Immunology.
- Lee, M. van der; Guchelaar, H.J. & Swen, J.J. (2021), Substrate specificity of CYP2D6 genetic variants, Pharmacogenomics 22(16): 1081-1089.
- Matic, M.; Nijenhuis, M.; Soree, B.; Boer-Veger, N.J. de; Buunk, A.M.; Houwink, E.J.F.; Mulder, H.; Rongen, G.A.P.J.M.; Weide, J. van der; Wilffert, B.; Swen, J.J.; Guchelaar, H.J.; Deneer, V.H.M. & Schaik, R.H.N. van (2021), Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone), European Journal of Human Genetics.
- Lee, M. van der; Allard, W.G.; Vossen, R.H.A.M.; Baak-Pablo, R.F.; Menafra, R.; Deiman, B.A.L.M.; Deenen, M.J.; Neven, P.; Johansson, I.; Gastaldello, S.; Ingelman-Sundberg, M.; Guchelaar, H.J.; Swen, J.J. & Anvar, S.Y. (2021), Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data, Science Translational Medicine 13(603).
- Brouwer, J.M.J.L.; Nijenhuis, M.; Soree, B.; Guchelaar, H.J.; Swen, J.J.; Schaik, R.H.N. van; Weide, J. van der; Rongen, G.A.P.J.M.; Buunk, A.M.; Boer-Veger, N.J. de; Houwink, E.J.F.; Westrhenen, R. van; Wilffert, B.; Deneer, V.H.M. & Mulder, H. (2021), Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs, European Journal of Human Genetics.
- Zwart, T.C.; Guchelaar, H.J.; Boog, P.J.M. van der; Swen, J.J.; Gelder, T. van; Fijter, J.W. de & Moes, D.J.A.R. (2021), Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation, Drug Discovery Today 26(11): 2527-2546.
- Tafazoli, A.; Guchelaar, H.J.; Miltyk, W.; Kretowski, A.J. & Swen, J.J. (2021), Applying next-generation sequencing platforms for pharmacogenomic testing in clinical practice, Frontiers in Pharmacology 12.
- Lee, M. van der; Rowell, W.J.; Menafra, R.; Guchelaar, H.J.; Swen, J.J. & Anvar, S.Y. (2021), Application of long-read sequencing to elucidate complex pharmacogenomic regions, Pharmacogenomics Journal 22.
- Martial, L.C.; Biewenga, M.; Ruijter, B.N.; Keizer, R.; Swen, J.J.; Hoek, B. van & Moes, D.J.A.R. (2021), Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients, British Journal of Clinical Pharmacology 87(11).
- Zwart, T.C.; Vries, A.P.J. de; Engbers, A.G.J.; Dam, R.E.; Boog, P.J.M. van der; Swen, J.J.; Keizer, R.J.; Dalton, R.N.; Guchelaar, H.J.; Fijter, J.W. de & Moes, D.J.A.R. (2021), Model-based estimation of iohexol plasma clearance for pragmatic renal function determination in the renal transplantation setting, Clinical Pharmacokinetics 60.
- Sanchez-Spitman, A.B.; Swen, J.J.; Dezentje, V.O.; Moes, D.J.A.R.; Gelderblom, H. & Guchelaar, H.J. (2021), Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse, Scientific Reports 11(1).
- Bergan, S.; Brunet, M.; Hesselink, D.A.; Johnson-Davis, K.L.; Kunicki, P.K.; Lemaitre, F.; Marquet, P.; Molinaro, M.; Noceti, O.; Pattanaik, S.; Pawinski, T.; Seger, C.; Shipkova, M.; Swen, J.J.; Gelder, T. van; Venkataramanan, R.; Wieland, E.; Woillard, J.B.; Zwart, T.C.; Barten, M.J.; Budde, K.; Dieterlen, M.T.; Elens, L.; Haufroid, V.; Masuda, S.; Millan, O.; Mizuno, T.; Moes, D.J.A.R.; Oellerich, M.; Picard, N.; Salzmann, L.; Tonshoff, B.; Schaik, R.H.N. van; Vethe, N.T.; Vinks, A.A.; Wallemacq, P.; Asberg, A. & Langman, L.J. (2021), Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Therapeutic Drug Monitoring 43(2): 150-200.
- Gelder, T. van; Etsouli, O.; Moes, D.J. & Swen, J.J. (2020), Comparison of the impact of pharmacogenetic variability on the PK of slow release and immediate release tacrolimus formulations, Genes 11(10).
- Jong, L.M. de; Jiskoot, W.; Swen, J.J. & Manson, M.L. (2020), Distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: lessons from experimental models and a potential role for pharmacogenetics, Genes 11(12).
- Yin, A.Y.; Ettaieb, M.H.T.; Swen, J.J.; Deun, L. van; Kerkhofs, T.M.A.; Straaten, R.J.H.M. van der; Corssmit, E.P.M.; Gelderblom, H.; Kerstens, M.N.; Feelders, R.A.; Eekhoff, M.; Timmers, H.J.L.M.; D'Avolio, A.; Cusato, J.; Guchelaar, H.J.; Haak, H.R. & Moes, D.J.A.R. (2020), Population pharmacokinetic and pharmacogenetic analysis of mitotane in patients with adrenocortical carcinoma, Clinical Pharmacokinetics 60.
- Wouden, C.H. van der; Bohringer, S.; Cecchin, E.; Cheung, K.C.; Davila-Fajardo, C.L.; Deneer, V.H.M.; Dolzan, V.; Ingelman-Sundberg, M.; Jonsson, S.; Karlsson, M.O.; Kriek, M.; Mitropoulou, C.; Patrinos, G.P.; Pirmohamed, M.; Rial-Sebbag, E.; Samwald, M.; Schwab, M.; Steinberger, D.; Stingl, J.; Sunder-Plassmann, G.; Toffoli, G.; Turner, R.M.; Rhenen, M.H. van; Zwet, E. van; Swen, J.J.; Guchelaar, H.J. & Ubiquitous Pharmacogenomics Consor (2020), Generating evidence for precision medicine, Pharmacogenetics and Genomics 30(6): 131-144.
- Sanchez-Spitman, A.B.; Moes, D.J.A.R.; Swen, J.J.; Dezentj?, V.O.; Lambrechts, D.; Neven, P.; Gelderblom, H. & Guchelaar, H.J. (2020), Exposure-response analysis of endoxifen serum concentrations in early-breast cancer, Cancer Chemotherapy and Pharmacology 85(6): 1141-1152.
- Klomp, S.D.; Manson, M.L.; Guchelaar, H.J. & Swen, J.J. (2020), Phenoconversion of cytochrome P450 metabolism: a systematic review, Journal of Clinical Medicine 9(9).
- Lee, M. van der; Kriek, M.; Guchelaar, H.J. & Swen, J.J. (2020), Technologies for pharmacogenomics: a review, Genes 11(12).
- Gelder, T. van; Meziyerh, S.; Swen, J.J.; Vries, A.P.J. de & Moes, D.J.A.R. (2020), The clinical impact of the C-0/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients, Frontiers in Pharmacology 11.
- Manson, L.E.N.; Swen, J.J. & Guchelaar, H.J. (2020), Diagnostic test criteria for HLA genotyping to prevent drug hypersensitivity reactions: a systematic review of actionable HLA recommendations in CPIC and DPWG guidelines, Frontiers in Pharmacology 11.
- Wouden, C.H. van der; Paasman, E.; Teichert, M.; Crone, M.R.; Guchelaar, H.J. & Swen, J.J. (2020), Assessing the implementation of pharmacogenomic panel-testing in primary care in the Netherlands utilizing a theoretical framework, Journal of Clinical Medicine 9(3).
- Hulshof, E.C.; Lurvink, R.J.; Caserta, N.; Hingh, I.H.J.T. de; Wezel, T. van; Bohringer, S.; Swen, J.J.; Gelderblom, H.; Guchelaar, H.J. & Deenen, M.J. (2020), Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases, European Journal of Surgical Oncology 46(10): 1925-1931.
- Lunenburg, C.A.T.C.; Wouden, C.H. van der; Nijenhuis, M.; Crommentuijn-van Rhenen, M.H.; Boer-Veger, N.J. de; Buunk, A.M.; Houwink, E.J.F.; Mulder, H.; Rongen, G.A.; Schaik, R.H.N. van; Weide, J. van der; Wilffert, B.; Deneer, V.H.M.; Swen, J.J. & Guchelaar, H.J. (2020), Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines, European Journal of Human Genetics 28(4): 508-517.
- Eektimmerman, F.; Swen, J.J.; Madhar, M.B.; Allaart, C.F. & Guchelaar, H.J. (2020), Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review, Pharmacogenomics Journal 20(2): 159-168.
- Overkleeft, R.; Tommel, J.; Evers, A.W.M.; Dunnen, J.T. den; Roos, M.; Hoefmans, M.J.; Schrader, W.E.; Swen, J.J.; Numans, M.E. & Houwink, E.J.F. (2020), Using personal genomic data within primary care, Genes 11(12).
- Wouden, C.H. van der; Rhenen, M.H. van; Jama, W.O.M.; Ingelman-Sundberg, M.; Lauschke, V.M.; Konta, L.; Schwab, M.; Swen, J.J. & Guchelaar, H.J. (2020), One non-believer: response to "Obviously Nine Believers: Actionable Germline Genetic Variants for Pre-emptive Pharmacogenetic Testing".
- Caudle, K.E.; Sangkuhl, K.; Whirl-Carrillo, M.; Swen, J.J.; Haidar, C.E.; Klein, T.E.; Gammal, R.S.; Relling, M.V.; Scott, S.A.; Hertz, D.L.; Guchelaar, H.J. & Gaedigk, A. (2020), Standardizing CYP2D6 genotype to phenotype translation, Clinical and Translational Science 13(1): 116-124.
- Sanchez-Spitman, A.B.; Swen, J.J.; Dezentje, V.O.; Moes, D.J.A.R.; Gelderblom, H. & Guchelaar, H.J. (2019), Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen, Expert Review of Clinical Pharmacology 12(6): 523-536.
- Guchelaar, H.J.; Sanchez-Spitman, A.; Dezentje, V.; Bohringer, S.; Swen, J.; Neven, P. & Gelderblom, H. (2019), Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM Reply, Journal of Clinical Oncology 37(22): 1984-+.
- Sanchez-Spitman, A.; Dezentje, V.; Swen, J.; Moes, D.J.A.R.; Bohringer, S.; Batman, E.; Druten, E. van; Smorenburg, C.; Bochove, A. van; Zeillemaker, A.; Jongen, L.; , M. los; Neven, P.; Gelderblom, H. & Guchelaar, H.J. (2019), Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study, Journal of Clinical Oncology 37(8): 636-+.
- Henricks, L.M.; Lunenburg, C.A.T.C.; Man, F.M. de; Meulendijks, D.; Frederix, G.W.J.; Kienhuis, E.; Creemers, G.J.; Baars, A.; Dezentje, V.O.; Imholz, A.L.T.; Jeurissen, F.J.F.; Portielje, J.E.A.; Jansen, R.L.H.; Hamberg, P.; Tije, A.J. ten; Droogendijk, H.J.; Koopman, M.; Nieboer, P.; Poel, M.H.W. van de; Mandigers, C.M.P.W.; Rosing, H.; Beijnen, J.H.; Werkhoven, E. van; Kuilenburg, A.B.P. van; Schaik, R.H.N. van; Mathijssen, R.H.J.; Swen, J.J.; Gelderblom, H.; Cats, A.; Guchelaar, H.J. & Schellens, J.H.M. (2019), A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy, European Journal of Cancer 107: 60-67.
- Lee, M. van der; Allard, W.G.; Bollen, S.; Santen, G.W.E.; Ruivenkamp, C.A.L.; Hoffer, M.J.V.; Kriek, M.; Guchelaar, H.J.; Anvar, S.Y. & Swen, J.J. (2019), Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics, Clinical Pharmacology and Therapeutics.
- Shekhani, R.; Steinacher, L.; Swen, J.J. & Ingelman-Sundberg, M. (2019), Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements, Clinical Pharmacology and Therapeutics.
- Bank, P.C.D.; Swen, J.J.; Schaap, R.D.; Klootwijk, D.B.; Baak-Pablo, R. & Guchelaar, H.J. (2019), A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care, European Journal of Human Genetics 27(10): 1532-1541.
- Yin, A.Y.; Moes, D.J.A.R.; Hasselt, J.G.C. van; Swen, J.J. & Guchelaar, H.J. (2019), A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors, CPT: Pharmacometrics and Systems Pharmacology 8(10): 720-737.
- Eektimmerman, F.; Allaart, C.F.; Hazes, J.M.W.; Broeder, A.A. den; Fransen, J.; Swen, J.J. & Guchelaar, H.J. (2019), Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients, Pharmacogenomics 20(2): 85-93.
- Wouden, C.H. van der; Rhenen, M.H. van; Jama, W.O.M.; Ingelman-Sundberg, M.; Lauschke, V.M.; Konta, L.; Schwab, M.; Swen, J.J. & Guchelaar, H.J. (2019), Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing, Clinical Pharmacology and Therapeutics 106(4): 866-873.
- Just, K.S.; Turner, R.M.; Dolzan, V.; Cecchin, E.; Swen, J.J.; Gurwitz, D. & Stingl, J.C. (2019), Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts, Clinical Pharmacology and Therapeutics 106(2): 313-316.
- Bank, P.C.D.; Swen, J.J. & Guchelaar, H.J. (2019), Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands, BMC Medicine 17.
- Wouden, C.H. van der; Bank, P.C.D.; Ozokcu, K.; Swen, J.J. & Guchelaar, H.J. (2019), Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact, Genes 10(6).
- Lunenburg, C.A.T.C.; Guchelaar, H.J.; Schaik, R.H.N. van; Neumaier, M. & Swen, J.J. (2019), Confirmation practice in pharmacogenetic testing; how good is good enough?, Clinica Chimica Acta 490: 77-80.
- Verboom, M.C.; Kloth, J.S.L.; Swen, J.J.; Sleijfer, S.; Reyners, A.K.L.; Steeghs, N.; Mathijssen, R.H.J.; Gelderblom, H. & Guchelaar, H.J. (2019), Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors, Pharmacogenomics Journal 19(5): 473-479.
- Amstutz, U.; Henricks, L.M.; Offer, S.M.; Barbarino, J.; Schellens, J.H.M.; Swen, J.J.; Klein, T.E.; McLeod, H.L.; Caudle, K.E.; Diasio, R.B. & Schwab, M. (2018), Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update, Clinical Pharmacology and Therapeutics 103(2): 210-216.
- Blagec, K.; Koopmann, R.; Crommentuijn-van Rhenen, M.; Holsappel, I.; Wouden, C.H. van der; Konta, L.; Xu, H.; Steinberger, D.; Just, E.; Swen, J.J.; Guchelaar, H.J. & Samwald, M. (2018), Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project, Journal of the American Medical Informatics Association 25(7): 893-898.
- Kloth, J.S.L.; Verboom, M.C.; Swen, J.J.; Straaten, T. van der; Sleijfer, S.; Reyners, A.K.L.; Steeghs, N.; Gelderblom, H.; Guchelaar, H.J. & Mathijssen, R.H.J. (2018), Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib, Pharmacogenomics Journal 18(1): 49-55.
- Bank, P.C.D.; Caudle, K.E.; Swen, J.J.; Gammal, R.S.; Whirl-Carrillo, M.; Klein, T.E.; Relling, M.V. & Guchelaar, H.J. (2018), Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group, Clinical Pharmacology and Therapeutics 103(4): 599-618.
- Bank, P.C.D.; Swen, J.J. & Guchelaar, H.J. (2018), A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands, Pharmacogenomics 19(4): 311-319.
- Liu, X.Y.; Swen, J.J.; Diekstra, M.H.M.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.J.; Vermeulen, S.H.; Oosterwijk, E.; Junker, K.; Roessler, M.; Alexiusdottir, K.; Sverrisdottir, A.; Radu, M.T.; Ambert, V.; Eisen, T.; Warren, A.; Rodriguez-Antona, C.; Garcia-Donas, J.; Bohringer, S.; Koudijs, K.K.M.; Kiemeney, L.A.L.M.; Rini, B.I. & Guchelaar, H.J. (2018), A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma, Clinical Cancer Research 24(10): 2350-2356.
- Eektimmerman, F.; Swen, J.J.; Bohringer, S.; Aslibekyan, S.; Allaart, C.F. & Guchelaar, H.J. (2018), SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients, Pharmacogenomics 19(7): 613-619.
- Maagdenberg, H.; Bierings, M.B.; Ommen, C.H. van; Meer, F.J.M. van der; Appel, I.M.; Tamminga, R.Y.J.; Cessie, S. le; Swen, J.J.; Straaten, T. van der; Boer, A. de & Maitland-van der Zee, A.H. (2018), Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients, Pharmacogenomics 19(15): 1195-1202.
- Sanchez-Spitman, A.B.; Dezentje, V.O.; Swen, J.J.; Moes, D.J.A.R.; Gelderblom, H. & Guchelaar, H.J. (2018), Genetic polymorphisms of 3-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy, Breast Cancer Research and Treatment 172(2): 401-411.
- Henricks, L.M.; Lunenburg, C.A.T.C.; Man, F.M. de; Meulendijks, D.; Frederix, G.W.J.; Kienhuis, E.; Creemers, G.J.; Baars, A.; Dezentje, V.O.; Imholz, A.L.T.; Jeurissen, F.J.F.; Portielje, J.E.A.; Jansen, R.L.H.; Hamberg, P.; Tije, A.J. ten; Droogendijk, H.J.; Koopman, M.; Nieboer, P.; Poel, M.H.W. van de; Mandigers, C.M.P.W.; Rosing, H.; Beijnen, J.H.; Werkhoven, E. van; Kuilenburg, A.B.P. van; Schaik, R.H.N. van; Mathijssen, R.H.J.; Swen, J.J.; Gelderblom, H.; Cats, A.; Guchelaar, H.J. & Schellens, J.H.M. (2018), DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis, Lancet Oncology 19(11): 1459-1467.
- Maagdenberg, H.; Bierings, M.B.; Ommen, C.H. van; Meer, F.J.M. van der; Appel, I.M.; Tamminga, R.Y.J.; Cessie, S. le; Swen, J.J.; Straaten, T. van der; Boer, A. de & Maitland-van der Zee, A.H. (2018), The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study, Journal of Thrombosis and Haemostasis 16(9): 1732-1742.
- Zwart, T.C.; Gokoel, S.R.M.; Boog, P.J.M. van der; Fijter, J. de; Kweekel, D.M.; Swen, J.J.; Guchelaar, H.J. & Moes, D.J.A.R. (2018), Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device, British Journal of Clinical Pharmacology 84(12): 2889-2902.
- Lunenburg, C.A.T.C.; Henricks, L.M.; Dreussi, E.; Peters, F.P.; Fiocco, M.; Meulendijks, D.; Toffoli, G.; Guchelaar, H.J.; Swen, J.J.; Cecchin, E.; Schellens, J.H.M. & Gelderblom, H. (2018), Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers, European Journal of Cancer 104: 210-218.
- Lunenburg, C.A.T.C.; Henricks, L.M.; Kuilenburg, A.B.P. van; Mathijssen, R.H.J.; Schellens, J.H.M.; Gelderblom, H.; Guchelaar, H.J. & Swen, J.J. (2018), Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants, Genes 9(12).
- Swen, J.J.; Nijenhuis, M.; Rhenen, M. van; Boer-Veger, N.J. de; Buunk, A.M.; Houwink, E.J.F.; Mulder, H.; Rongen, G.A.; Schaik, R.H.N. van; Weide, J. van der; Wilffert, B.; Deneer, V.H.M.; Guchelaar, H.J. & Royal Dutch Pharmacists Assoc KNMP (2018), Pharmacogenetic Information in Clinical Guidelines: The European Perspective, Clinical Pharmacology and Therapeutics 103(5): 795-801.
- Manson, L.E.N.; Wouden, C.H. van der; Swen, J.J. & Guchelaar, H.J. (2017), The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen, Pharmacogenomics 18(11): 1041-1045.
- Verboom, M.C.; Visser, L.; Kouwen, S.; Swen, J.J.; Diepstraten, J.; Posthuma, W.F.; Gelderblom, H.; Lammeren, D. van & Wilms, E.B. (2017), Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients, Pharmacogenetics and Genomics 27(6): 223-226.
- Vanhove, T.; Bouwsma, H.; Hilbrands, L.; Swen, J.J.; Spriet, I.; Annaert, P.; Vanaudenaerde, B.; Verleden, G.; Vos, R. & Kuypers, D.R.J. (2017), Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients, American Journal of Transplantation 17(9): 2372-2380.
- Hicks, J.K.; Sangkuhl, K.; Swen, J.J.; Ellingrod, V.L.; Muller, D.J.; Shimoda, K.; Bishop, J.R.; Kharasch, E.D.; Skaar, T.C.; Gaedigk, A.; Dunnenberger, H.M.; Klein, T.E.; Caudle, K.E. & Stingl, J.C. (2017), Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update, Clinical Pharmacology and Therapeutics 102(1): 37-44.
- Liu, X.Y.; Fiocco, M.; Swen, J.J. & Guchelaar, H.J. (2017), Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis, Acta Oncologica 56(4): 582-589.
- Diekstra, M.; Belaustegui, A.; Swen, J.J.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.; Garcia-Donas, J.; Rodriguez-Antona, C.; Rini, B.I. & Guchelaar, H.J. (2017), Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma, Pharmacogenomics Journal 17(1): 42-46.
- Eektimmerman, F.; Swen, J.J.; Bohringer, S.; Huizinga, T.W.J.; Kooloos, W.M.; Allaart, C.F. & Guchelaar, H.J. (2017), Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis, Pharmacogenomics 18(10): 945-953.
- Wouden, C.H. van der; Cambon-Thomsen, A.; Cecchin, E.; Cheung, K.C.; Davila-Fajardo, C.L.; Deneer, V.H.; Dolzan, V.; Ingelman-Sundberg, M.; Jonsson, S.; Karlsson, M.O.; Kriek, M.; Mitropoulou, C.; Patrinos, G.P.; Pirmohamed, M.; Samwald, M.; Schaeffeler, E.; Schwab, M.; Steinberger, D.; Stingl, J.; Sunder-Plassmann, G.; Toffoli, G.; Turner, R.M.; Rhenen, M. van; Swen, J.J.; Guchelaar, H.J. & Ubiquitous Pharmacogenomics Consor (2017), Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium, Clinical Pharmacology and Therapeutics 101(3): 341-358.
- Buermans, H.P.J.; Vossen, R.H.A.M.; Anvar, S.Y.; Allard, W.G.; Guchelaar, H.J.; White, S.J.; Dunnen, J.T. den; Swen, J.J. & Straaten, T. van der (2017), Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing, Human Mutation 38(3): 310-316.
- Apellaniz-Ruiz, M.; Diekstra, M.H.; Roldan, J.M.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.J.; Swen, J.J.; Bohringer, S.; Garcia-Donas, J.; Rini, B.I.; Guchelaar, H.J. & Rodriguez-Antona, C. (2017), Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma, Pharmacogenetics and Genomics 27(6): 227-231.
- Bank, P.C.D.; Swen, J.J. & Guchelaar, H.J. (2017), A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations, Pharmacogenomics 18(3): 215-225.
- Liu, X.Y.; Swen, J.J.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.J.; Rodriguez-Antona, C.; Garcia-Donas, J.; Rini, B.I. & Guchelaar, H.J. (2017), Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients, Oncotarget 8(1): 1204-1212.
- Diekstra, M.H.; Liu, X.Y.; Swen, J.J. & Guchelaar, H.J. (2017), What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?, Pharmacogenomics 18(1): 1-4.
- Sanchez-Spitman, A.B.; Moes, D.J.A.R.; Gelderblom, H.; Dezentje, V.O.; Swen, J.J. & Guchelaar, H.J. (2017), The effect of rs5758550 on CYP2D6(star)2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen, Pharmacogenomics 18(12): 1125-1132.
- Diekstra, M.H.; Fritsch, A.; Kanefendt, F.; Swen, J.J.; Moes, D.J.A.R.; Sorgel, F.; Kinzig, M.; Stelzer, C.; Schindele, D.; Gauler, T.; Hauser, S.; Houtsma, D.; Roessler, M.; Moritz, B.; Mross, K.; Bergmann, L.; Oosterwijk, E.; Kiemeney, L.A.; Guchelaar, H.J. & Jaehde, U. (2017), Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer, CPT: Pharmacometrics and Systems Pharmacology 6(9): 604-613.
- Just, K.S.; Steffens, M.; Swen, J.J.; Patrinos, G.P.; Guchelaar, H.J. & Stingl, J.C. (2017), Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx), European Journal of Clinical Pharmacology 73(10): 1247-1252.
- Verboom, M.C.; Kloth, J.S.L.; Swen, J.J.; Straaten, T. van der; Bovee, J.V.M.G.; Sleijfer, S.; Reyners, A.K.L.; Mathijssen, R.H.J.; Guchelaar, H.J.; Steeghs, N. & Gelderblom, H. (2017), Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib, European Journal of Cancer 86: 226-232.
- Spitman, A.B.; Moes, D.J.A.R.; Gelderblom, H.; Dezentje, V.O.; Swen, J. & Guchelaar, H.J. (2017), Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism, European Journal of Clinical Pharmacology 73(12): 1589-1598.
- Lunenburg, C.A.T.C.; Swen, J.J.; Guchelaar, H.J. & Gelderblom, H. (2017), Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil, Journal of Gastrointestinal Cancer 48(1): 117-118.
- Lunenburg, C.A.T.C.; Henricks, L.M.; Guchelaar, H.J.; Swen, J.J.; Deenen, M.J.; Schellens, J.H.M. & Gelderblom, H. (2016), Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time, European Journal of Cancer 54: 40-48.
- Diekstra, M.H.M.; Swen, J.J.; Gelderblom, H. & Guchelaar, H.J. (2016), A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review, Expert Review of Molecular Diagnostics 16(5): 605-618.
- Lunenburg, C.A.T.C.; Staveren, M.C. van; Gelderblom, H.; Guchelaar, H.J. & Swen, J.J. (2016), Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients, Pharmacogenomics 17(7): 721-729.
- Moes, D.J.A.R.; Bent, S.A.S. van der; Swen, J.J.; Straaten, T. van der; Inderson, A.; Olofsen, E.; Verspaget, H.W.; Guchelaar, H.J.; Hartigh, J. den & Hoek, B. van (2016), Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients, European Journal of Clinical Pharmacology 72(2): 163-174.
- Groot, S. de; Charehbili, A.; Laarhoven, H.W.M. van; Mooyaart, A.L.; Dekker-Ensink, N.G.; Ven, S. van de; Janssen, L.G.M.; Swen, J.J.; Smit, V.T.H.B.M.; Heijns, J.B.; Kessels, L.W.; Straaten, T. van der; Bohringer, S.; Gelderblom, H.; Hoeven, J.J.M. van der; Guchelaar, H.J.; Pijl, H.; Kroep, J.R. & Dutch Breast Canc Res Grp (2016), Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01), Breast Cancer Research 18.
- Moes, D.J.A.R.; Swen, J.J.; Bent, S.A.S. van der; Straaten, T. van der; Inderson, A.; Olofsen, E.; Verspaget, H.W.; Guchelaar, H.J.; Hartigh, J. den & Hoek, B. van (2016), Response: Limited sampling strategies for once daily tacrolimus exposure monitoring, European Journal of Clinical Pharmacology 72(6): 775-776.
- Wouden, C.H. van der; Swen, J.J.; Samwald, M.; Mitropoulou, C.; Schwab, M.; Guchelaar, H.J. & Ubiquitous-Pharmacogenomics (2016), A brighter future for the implementation of pharmacogenomic testing, European Journal of Human Genetics 24(12): 1658-1660.
- Diekstra, M.H.M.; Swen, J.J.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.J.; Rodriguez-Antona, C.; Garcia-Donas, J.; Rini, B.I. & Guchelaar, H.J. (2015), CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma, European Urology 68(4): 621-629.
- Diekstra, M.; Swen, J.J.; , E. boven; Castellano, D.; Ganapathi, R.; Gelderblom, H.; Mathijssen, R.H.; Rodriguez-Antona, C.; Garcia-Donas, J.; Rini, B. & Guchelaar, H. (2015), A MULTICENTER VALIDATION STUDY OF GENETIC POLYMORPHISMS ASSOCIATED WITH TOXICITY AND EFFICACY OF SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA., Clinical Pharmacology and Therapeutics 97: S58-S58.
- Mirzakhani, H.; Dormolen, J. van; Weide, K. van der; Guchelaar, H.J.; Noorden, M.S. van & Swen, J. (2015), Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy, Pharmacogenetics and Genomics 25(10): 515-517.
- Liu, X.; Diekstra, M.H.; Swen, J.J.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.; Rodriguez-Antona, C.; Garcia-Donas, J.; Rini, B.I. & Guchelaar, H. (2015), Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma, European Journal of Clinical Pharmacology 71(12): 1477-1484.
- Birdwell, K.A.; Decker, B.; Barbarino, J.M.; Peterson, J.F.; Stein, C.M.; Sadee, W.; Wang, D.; Vinks, A.A.; He, Y.; Swen, J.J.; Leeder, J.S.; Schaik, R.H. van; Thummel, K.E.; Klein, T.E.; Caudle, K.E. & MacPhee, I.A.M. (2015), Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing, Clinical Pharmacology and Therapeutics 98(1): 19-24.
- Huis-Tanja, L.H. van; Ewing, E.; Straaten, R.J.H.M. van der; Swen, J.J.; Baak-Pablo, R.F.; Punt, C.J.A.; Gelderblom, A.J. & Guchelaar, H.J. (2015), Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients, Pharmacogenetics and Genomics 25(6): 279-288.
- Schully, S.D.; Lam, T.K.; Dotson, W.D.; Chang, C.Q.; Aronson, N.; Birkeland, M.L.; Brewster, S.J.; Boccia, S.; Buchanan, A.H.; Calonge, N.; Calzone, K.; Djulbegovic, B.; Goddard, K.A.B.; Klein, R.D.; Klein, T.E.; Lau, J.; Long, R.; Lyman, G.H.; Morgan, R.L.; Palmer, C.G.S.; Ling, M.V.R.; Rubinstein, W.S.; Swen, J.J.; Terry, S.F.; Williams, M.S. & Khoury, M.J. (2015), Evidence synthesis and guideline development in genomic medicine: current status and future prospects, Genetics in Medicine 17(1): 63-67.
- Charehbili, A.; Groot, S. de; Straaten, T. van der; Swen, J.J.; Pijl, H.; Gelderblom, H.; Velde, C.J.H. van de; Nortier, J.W.R.; Guchelaar, H.J. & Kroep, J.R. (2015), Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia, Pharmacogenomics 16(11): 1265-1274.
- Davila-Fajardo, C.L.; Straaten, T. van der; Baak-Pablo, R.; Caballero, C.M.; Barrera, J.C.; Huizinga, T.W.; Guchelaar, H.J. & Swen, J.J. (2015), FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis, Pharmacogenomics 16(4): 373-381.
- Henricks, L.M.; Lunenburg, C.A.T.C.; Meulendijks, D.; Gelderblom, H.; Cats, A.; Swen, J.J.; Schellens, J.H.M. & Guchelaar, H.J. (2015), Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score, Pharmacogenomics 16(11): 1275-1284.
- Bank, P.C.D.; Swen, J.J.; Guchelaar, H.J. & Straaten, T. van der (2015), GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population, Pharmacogenomics 16(7): 681-687.
- Mirzakhani, H.; Noorden, M.S. van; Swen, J.; Nozari, A. & Guchelaar, H.J. (2015), Pharmacogenetics in electroconvulsive therapy and adjunctive medications, Pharmacogenomics 16(9): 1015-1031.
- Brink, M.H. ten; Zwaveling, J.; Swen, J.J.; Bredius, R.G.M.; Lankester, A.C. & Guchelaar, H.J. (2014), Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics, Drug Discovery Today 19(10): 1572-1586.
- Guchelaar, H.J.; Gelderblom, H.; Straaten, T.D.; Schellens, J.H.M. & Swen, J.J. (2014), Pharmacogenetics in the Cancer Clinic: From Candidate Gene Studies to Next-Generation Sequencing.
- Diekstra, M.H.M.; Klumpen, H.J.; Lolkema, M.P.J.K.; Yu, H.; Kloth, J.S.L.; Gelderblom, H.; Schaik, R.H.N. van; Gurney, H.; Swen, J.J.; Huitema, A.D.R.; Steeghs, N. & Mathijssen, R.H.J. (2014), Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662, Clinical Pharmacology and Therapeutics 96(1): 81-89.
- Hicks, J.K.; Swen, J.J. & Gaedigk, A. (2014), Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization, Current Drug Metabolism 15(2): 218-232.
- Caudle, K.E.; Klein, T.E.; Hoffman, J.M.; Muller, D.J.; Whirl-Carrillo, M.; Gong, L.; McDonagh, E.M.; Sangkuhl, K.; Thorn, C.F.; Schwab, M.; Agundez, J.A.G.; Freimuth, R.R.; Huser, V.; Lee, M.T.M.; Iwuchukwu, O.F.; Crews, K.R.; Scott, S.A.; Wadelius, M.; Swen, J.J.; Tyndale, R.F.; Stein, C.M.; Roden, D.; Relling, M.V.; Williams, M.S. & Johnson, S.G. (2014), Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process, Current Drug Metabolism 15(2): 209-217.
- Bank, P.C.D.; Guchelaar, H.J. & Swen, J.J. (2014), Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule, Internal and Emergency Medicine 9(4): 481-482.
- Nagtegaal, M.J.; Swen, J.J.; Hanff, L.M.; Schimmel, K.J.M. & Guchelaar, H.J. (2014), Pharmacogenetics of taste: turning bitter pills sweet?, Pharmacogenomics 15(1): 111-119.
- Bank, P.C.; Swen, J.J. & Guchelaar, H.J. (2014), Pharmacogenetic biomarkers for predicting drug response, Expert Review of Molecular Diagnostics 14(6): 723-735.
- Moes, D.J.A.R.; Bent, S.A.S. van der; Swen, J.J.; Straaten, T.; Verspaget, H.W.; Guchelaar, H.J.; Hartigh, J. den & Hoek, B. van (2014), Population Pharmacokinetics and Pharmacogenetics of Once Daily Tacrolimus Formulation in Liver Transplant Patients., Liver Transplantation 20: S106-S107.
- Brink, M. ten; Bavel, T. van; Swen, J.J.; Straaten, T. van der; Bredius, R.G.; Lankester, A.C.; Zwaveling, J. & Guchelaar, H. (2014), THE ROLE OF GENETIC VARIANTS GSTA1 AND CYP39A1 AND ONTOGENESIS ON BUSULFAN CLEARANCE IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC SCT., Clinical Pharmacology and Therapeutics 95: S100-S100.
- Davila-Fajardo, C.L.; Swen, J.J.; Straaten, T. van der & Guchelaar, H.J. (2013), Centres of Excellence Course in Pharmacogenetics, 25-28 June 2012, European Journal of Hospital Pharmacy 20(2): 132-132.
- Brink, M.H. ten; Bavel, T. van; Swen, J.J.; Straaten, T. van der; Bredius, R.G.M.; Lankester, A.C.; Zwaveling, J. & Guchelaar, H.J. (2013), Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation, Pharmacogenomics 14(14): 1683-1690.
- Moes, D.J.A.R.; Swen, J.J.; Hartigh, J. den; Straaten, T. van der; Heide, J.J.H. van der; Bemelman, F.; Fijter, J.W. de & Guchelaar, H.J. (2013), Evaluating the Effect of CYP3A4 and CYP3A5 Polymorphisms on Cyclosporine, Everolimus and Tacrolimus Pharmacokinetics in Renal Transplantation Patients, Therapeutic Drug Monitoring 35(5): 672-672.
- Brink, M.H. ten; Swen, J.J.; Bohringer, S.; Wessels, J.A.M.; Straaten, T. van der; Marijt, E.W.A.; Borne, P.A. von dem; Zwaveling, J. & Guchelaar, H.J. (2013), Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients, Pharmacogenetics and Genomics 23(12): 675-683.
- Brink, M.H. ten; Straaten, T. van der; Bouwsma, H.; Baak-Pablo, R.; Guchelaar, H.J. & Swen, J.J. (2013), Pharmacogenetics in Transplant Patients: Mind the Mix, Clinical Pharmacology and Therapeutics 94(4): 443-444.
- Davila-Fajardo, C.L.; Swen, J.J.; Barrera, J.C. & Guchelaar, H.J. (2013), Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate, Pharmacogenomics 14(1): 63-73.
- Leeuwen, N. van; Swen, J.J.; Guchelaar, H.J. & 'tHart, L.M. (2013), The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs, Clinical Pharmacokinetics 52(10): 833-854.
- Caudle, K.E.; Thorn, C.F.; Klein, T.E.; Swen, J.J.; McLeod, H.L.; Diasio, R.B. & Schwab, M. (2013), Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing, Clinical Pharmacology and Therapeutics 94(6): 640-645.
- Hicks, J.K.; Swen, J.J.; Thorn, C.F.; Sangkuhl, K.; Kharasch, E.D.; Ellingrod, V.L.; Skaar, T.C.; Muller, D.J.; Gaedigk, A. & Stingl, J.C. (2013), Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants, Clinical Pharmacology and Therapeutics 93(5): 402-408.
- Brink, M.H. ten; Swen, J.J.; Zwaveling, J.; Straaten, T. van der; Wessels, J.A. & Guchelaar, H.J. (2013), EXPLORATORY ANALYSIS OF 1,936 SNPS IN 225 ADME GENES FOR ASSOCIATION WITH BUSULFAN CLEARANCE IN ADULT HEMATOPOIETIC STEM CELL RECIPIENTS, Clinical Pharmacology and Therapeutics 93: S87-S87.
- Brink, M.H. ten; Swen, J.J.; Zwaveling, J.; Straaten, T. van der; Wessels, J.A. & Guchelaar, H.J. (2013), EXPLORATORY ANALYSIS OF 1,936 SNPS IN 225 ADME GENES FOR ASSOCIATION WITH BUSULFAN CLEARANCE IN ADULT HEMATOPOIETIC STEM CELL RECIPIENTS, Clinical Pharmacology and Therapeutics 93: S5-S5.
- Swen, J.J.; Straaten, T. van der; Wessels, J.A.M.; Bouvy, M.L.; Vlassak, E.E.W.; Assendelft, W.J.J. & Guchelaar, H.J. (2012), Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19, European Journal of Clinical Pharmacology 68(4): 363-370.
- Swen, J.J.; Baak-Pablo, R.F.; Guchelaar, H.J. & Straaten, T. van der (2012), Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1 beta gene, Clinical Chemistry and Laboratory Medicine 50(2): 279-284.
- Swen, J.J. & Guchelaar, H.J. (2012), Just how feasible is pharmacogenetic testing in the primary healthcare setting?, Pharmacogenomics 13(5): 507-509.
- Straaten, T. van der; Guchelaar, H.J. & Swen, J.J. (2012), The challenges of developing a 'medical-grade' genome, Pharmacogenomics 13(4): 369-372.
- Swen, J.J.; Nijenhuis, M.; Boer, A. de; Grandia, L.; Maitland-van der Zee, A.H.; Mulder, H.; Rongen, G.A.P.J.M.; Schaik, R.H.N. van; Schalekamp, T.; Touw, D.J.; Weide, J. van der; Wilffert, B.; Deneer, V.H.M. & Guchelaar, H.J. (2011), Pharmacogenetics: From Bench to Byte-An Update of Guidelines.
- Swen, J.J.; Guchelaar, H.J.; Baak-Pablo, R.F.; Assendelft, W.J.J. & Wessels, J.A.M. (2011), Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment, Pharmacogenetics and Genomics 21(8): 461-468.
- Swen, J.J.; Straaten, T. van der; Wessels, J.A.M.; Bouvy, M.L.; Vlassak, E.E.W.; Assendelft, W.J.J. & Guchelaar, H.J. (2011), Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19., European Journal of Clinical Pharmacology.
- Swen, J.J. & Guchelaar, H.J. (2011), Pharmacogenetic dose recommendations in clinical practice, EJHP Practice 17(5): 28-29.
- Wilffert, B.; Swen, J.; Mulder, H.; Touw, D.; Maitland-Van der Zee, A.H.; Deneer, V. & KNMP Working Grp Pharmacogenetics (2011), From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics, International Journal of Clinical Pharmacy 33(1): 3-9.
- Swen, J.J. & Guchelaar, H.J. (2011), Comment: Global Formulary Review: How Do We Integrate Pharmacogenomic Information?, Annals of Pharmacotherapy 45(7-8): 1030-1030.
- Swen, J.J.; Wessels, J.A.; Assendelft, W.J. & Guchelaar, H.J. (2011), GENETIC RISK FACTORS FOR TYPE 2 DIABETES MELLITUS AND RESPONSE TO SULFONYLUREA TREATMENT., Clinical Pharmacology and Therapeutics 89: S76S76.
- Opdam, F.L.; Swen, J.J.; Wessels, J.A.M. & Gelderblom, H. (2011), SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Letter, Clinical Cancer Research 17(17): 5833-5834.
- Swen, J.J.; Wessels, J.A.M.; Krabben, A.; Assendelft, W.J.J. & Guchelaar, H.J. (2010), Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus, Pharmacogenomics 11(11): 1517-1523.
- Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, de Boer A, Conemans JMH, Egberts TCG, Klungel OH, Koopmans R, van der Weide J, Wilffert B, Guchelaar HJ & Deneer VHM (2008), Pharmacogenetics: From bench to byte, Clinical Pharmacology and Therapeutics 83(5).
- van der Straaten T, Swen J, Baak-Pablo R & Guchelaar HJ (2008), Use of plasmid-derived external quality control samples in pharmacogenetic testing, Pharmacogenomics 9(9).
- Swen JJ, Huizinga TW, Gelderblom H, de Vries EGE, Assendelft WJJ, Kirchheiner J & Guchelaar HJ (2007), Translating pharmacogenomics: Challenges on the road to the clinic, PLoS Medicine 4(8).
- Bevorderen van farmaceutisch onderzoek dmv ter beschikking stellen van financiële toelage.